Loading
A phase 2 trial of KC1036 in thymoma and thymic carcinoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
A Study of KC1036 in Patients with Advanced Thymic Tumors is a phase 2 interventional study registered as NCT05683886 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2023-02-22 and due to reach its primary completion in 2025-02. Interventions recorded: KC1036.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Beijing Konruns Pharmaceutical, KC1036 and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma and the tag pipeline.
Shares Thymic carcinoma, Thymoma and thymic carcinoma and the tag pipeline.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Beijing Konruns Pharmaceutical, KC1036.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3), Thymoma and thymic carcinoma.
Shares Thymic carcinoma, Thymoma (WHO types A, AB, B1, B2 and B3).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/